ERLOTINIB
Total Payments
$103,258
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $103,258 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $103,258 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1 trial of low dose daily erlotinib in combination with high dose twice weekly erlotinib in patients with EGFR mutant lung cancer | Astellas Pharma Global Development | $86,598 | 0 |
| Genomic landscape of EGFR mutant NSCLC prior to erlotinib and at the time of disease progression following erlotinib | Astellas Pharma Global Development | $8,160 | 0 |
| AN OPEN-LABEL, RANDOMIZED PHASE 3 EFFICACY STUDY OF ASP8273 VS. ERLOTINIB OR GEFITINIB IN FIRST-LINE TREATMENT OF PATIENTS WITH STAGE IIIBIV NON-SMALL CELL LUNG CANCER TUMORS WITH EGFR ACTIVATING MUTATIONS | Astellas Pharma Global Development | $6,500 | 0 |
| Phase II Study Of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients with EGFR Mutation Who Have Previously Progressed on an EGFR-TKI | Astellas Pharma Global Development | $2,000 | 0 |
Top Doctors Receiving Payments for ERLOTINIB
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Burlington, VT | $103,258 | 4 |
Ad
Manufacturing Companies
- Astellas Pharma Global Development $103,258
Product Information
- Type Drug
- Total Payments $103,258
- Total Doctors 0
- Transactions 4
About ERLOTINIB
ERLOTINIB is a drug associated with $103,258 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma Global Development.
Payment data is available from 2018 to 2018. In 2018, $103,258 was paid across 4 transactions to 0 doctors.
The most common payment nature for ERLOTINIB is "Unspecified" ($103,258, 100.0% of total).
ERLOTINIB is associated with 4 research studies, including "A Phase 1 trial of low dose daily erlotinib in combination with high dose twice weekly erlotinib in patients with EGFR mutant lung cancer" ($86,598).